AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

<u>Directions</u>: <u>The prescribing physician must sign and clearly print name (preprinted stamps not valid)</u> on this request. All other information may be filled in by office staff; <u>fax to 1-305-671-0200</u>. No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. <u>If the information provided is not complete, correct, or legible, the authorization process can be delayed.</u>

This is a group specific benefit

Continuous Glucose Monitors (CGM), Subcutaneous Insulin Pumps & Combination Devices

Drug Requested: (Check below the CGM that applies)

	S 110 que de la company de la			
	Formulary Pr	referred CGM's		
	FreeStyle Libre 1	□ FreeStyle Libre 2		
	Dexcom	□ FreeStyle Libre 3		
	<u> </u>	Medical Exception is required for all Non- submission of the following form:		
	Eversense ®	□ Guardian [™]		
		ION: Authorization may be delayed if incomplete.		
	nber Name:			
	nber AvMed #:			
Pres	criber Name:			
Pres	criber Signature:	Date:		
Offic	ce Contact Name:			
Phor	Phone Number: Fax Number:			
	OR NPI #:			
DR	RUG INFORMATION: Authorization may b	e delayed if incomplete.		
Drug	g Form/Strength:			
Dosi	ng Schedule:	Length of Therapy:		
Diag	gnosis:	ICD Code, if applicable:		
Woight		Data		

Quantity Limits:

<u>Dexcom</u>	<u>Freestyle</u>
• 1 receiver per lifetime	1 reader kit per lifetime
• 3 sensors per 30 days	2 sensors per 28 days
• 1 transmitter per 90 days	

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

P101	provided of request may be defined.				
	Cor	tinuous Glucose Monitors – Long Term Use			
Ler	Length of Authorization: Indefinite				
	Me	ember requires Long-term CGM device indicated by <u>ALL</u> the following:			
		Diagnosis of ONE of the following:			
		☐ Type 1 Diabetes Mellitus			
		☐ Type 2 Diabetes Mellitus			
		☐ Gestational Diabetes			
		Member requires a demanding insulin regimen of at least three or more insulin injections per day or current use of an insulin pump			
		Member or guardian consistently monitors blood glucose three or more times per day			
		Provider attests that the member is motivated and knowledgeable about use of CGMs, is adherent to diabetic treatment plan, and participates in ongoing education and support			
	Cor	tinuous Glucose Monitors – Short Term Use			
<u>Ler</u>	Length of Authorization: 1 month (30 days)				
	Me	ember requires Short-term CGM device indicated by <u>ALL</u> the following:			
		Diagnosis of ONE of the following:			
		☐ Type 1 Diabetes Mellitus			
		☐ Type 2 Diabetes Mellitus			
		☐ Gestational Diabetes			

(Continued on next page)

		☐ Member must demonstrate at least <u>ONE</u> of the following:				
		Observed increase in blood glucose levels that takes place in the early-morning (also known as The Dawn Phenomenon), known or suspected				
		☐ Hypoglycemia unawareness (i.e., member does not have symptoms with hypoglycemia)				
		□ Nocturnal hypoglycemia, known or suspected				
		☐ Postprandial hyperglycemia, known or suspected				
		☐ Significant change to diabetes treatment regimen (e.g., initiation of insulin, change from multiple dose insulin to insulin pump therapy)				
		☐ Unexplained hyperglycemia				
		Member requires short term blood glucose monitoring (i.e., 7-14 days)				
	Sub	ocutaneous Insulin Pumps and Combination Devices (Insulin Pump and CGM)				
<u>.</u> 1	the f	following criteria must be met:				
	Pro	ovider is an endocrinologist				
_	Pro	ovider must submit <u>ALL</u> the following documentation:				
		Confirmation of Diagnosis				
		Two weeks of current blood glucose results obtained within the last 30 days				
		Glycosylated hemoglobin (HbA1c) lab result obtained within the last 6 months				
_	Member must demonstrate at least ONE of the following:					
		Observed increase in blood glucose levels that takes place in the early-morning (also known as The Dawn Phenomenon) known or suspected				
		Hypoglycemia unawareness (i.e. member does not have symptoms with hypoglycemia)				
		Metabolic control is inadequate, due to inconsistencies in insulin absorption with mixed insulin regimens				
		Member requires a demanding insulin regimen of at least three or more insulin injections per day				
		Optimal glycemic control has not been achieved as demonstrated by a recurrent, severe hypoglycemic event that may have resulted in hospitalization				
_		ovider attests that the member is motivated and knowledgeable about use of requested device, is herent to diabetic treatment plan, and participates in ongoing education and support				
_	Fo	r members diagnosed with Gestational Diabetes, at least ONE of the following criteria must be met:				
		Member requires two or more insulin injections daily				
		Member has microalbuminuria >20 mcg/min				
		Member has proteinuria >120 mg/day				
		Member has a history of nephropathy				
		Member has a history of retinopathy				

(Continued on next page)

Replacement Device
Member has been previously approved for a CGM or insulin pump device
At least ONE of the following problems have occurred which limits the use of the member's current CGM or insulin pump device
☐ Abuse of equipment
☐ Misuse of equipment
☐ Reagent or instrument failure/defective devices
□ Defects in product design
□ Product instability
☐ Failure to perform according to performance characterized in package insert
☐ Incorrect test results (falsely elevated or decreased glucose results) that cause or contributed to an incorrect patient diagnosis and/or treatment
☐ Unexplained quality control (QC) failures
☐ Any other device problems that may compromise patient health or safety
Provider or member must submit documentation that the member's current CGM or insulin pump device is not under warranty, including the date of warranty expiration

Not all drugs may be covered under every Plan.

If a drug is non-formulary on a Plan, documentation of medical necessity will be required.

**Use of samples to initiate therapy does not meet step edit/preauthorization criteria. **

*Previous therapies will be verified through pharmacy paid claims or submitted chart notes. *